(S)-5-Aminomethyl-3-{3-fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-oxazolidin-2-one | 735276-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (S)-5-Aminomethyl-3-{3-fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-oxazolidin-2-one
• CAS: 735276-55-8
• 化学式: C₂₀H₂₂F₂N₄O₂
• 分子量: 388.417
• InChiKey: NPNVFCJBEPTUEZ-KRWDZBQOSA-N

反应信息

• 作为反应物：
  描述：

  (S)-5-Aminomethyl-3-{3-fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-oxazolidin-2-one 在 劳森试剂 、 TEA 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 生成 N-((S)-3-{3-Fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-2-oxo-oxazolidin-5-ylmethyl)-thioacetamide
  参考文献：
  名称：

  Synthesis and antibacterial activity of arylpiperazinyl oxazolidinones with diversification of the N-substituents

  摘要：

  A series of 4-arylpiperazin-1-yl-3-phenyloxazolidin-2-one derivatives with diversification of the N-substituents such as methylene O-linked heterocycles, thioamide, dithiocarbamate, thiourea, and thiocarbamate were synthesized and evaluated as antibacterial agents. Their in vitro activities (MIC) were evaluated against MRSA and VRE resistant Gram-positive strains such as Staphylococcus and Enterococcus. Most of the compounds were more potent in vitro but less active in vivo than linezolid. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.066
• 作为产物：
  描述：

  (R)-5-Azidomethyl-3-{3-fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-oxazolidin-2-one 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 生成 (S)-5-Aminomethyl-3-{3-fluoro-4-[4-(3-fluoro-phenyl)-piperazin-1-yl]-phenyl}-oxazolidin-2-one
  参考文献：
  名称：

  Synthesis and antibacterial activity of arylpiperazinyl oxazolidinones with diversification of the N-substituents

  摘要：

  A series of 4-arylpiperazin-1-yl-3-phenyloxazolidin-2-one derivatives with diversification of the N-substituents such as methylene O-linked heterocycles, thioamide, dithiocarbamate, thiourea, and thiocarbamate were synthesized and evaluated as antibacterial agents. Their in vitro activities (MIC) were evaluated against MRSA and VRE resistant Gram-positive strains such as Staphylococcus and Enterococcus. Most of the compounds were more potent in vitro but less active in vivo than linezolid. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.05.066